Company intelligence / Profile preview
DiaMedica Therapeutics
Minneapolis, Minnesota, United Statesdiamedica.com ↗
- Ownership
- Public · DMAC
- Employees
- ~40
- Development stage
- Phase 2
01
Overview
DiaMedica’s lead candidate DM199 (rinvecalinase alfa) is in Phase 2/3 trials for acute ischemic stroke and in Phase 2 for preeclampsia. The company recently dosed the first patient in its investigator-sponsored Phase 2 trial of DM199 for preeclampsia in South Africa. Topline data from Part 1A of this study are expected in the first half of 2025 to assess safety and blood pressure-lowering effects. The ReMEDy2 trial for acute ischemic stroke continues with site activations across the US and Canada; interim results are anticipated Q4 2025[5][7][8]. Preclinical work continues on DM300 for inflammatory diseases such as acute pancreatitis.
- Therapeutic areas
- Women's HealthGastroenterologyCardiovascular
- Modalities
- Large molecules (recombinant proteins), specifically recombinant human tissue kallikrein‐1 (KLK1)recombinant human ulinastatin[3][4][9]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Investigator-sponsored clinical collaboration with Stellenbosch University/Tygerberg Hospital, South Africa (for PE trial)[5].No major pharma partnerships disclosed as of current reporting.
04
Financials
- Market cap
- $355.1M
- Total revenue
- $0
- Enterprise value
- $311.8M
Beyond the preview
Go deeper on DiaMedica Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DiaMedica Therapeutics.